Savvy Updates, 10/17/22: Dexcom G7 Global Rollout, T2D Drugs Help T1Ds, BefA Gut Bacteria & Beta Cell Production, FDA TAP Pilot Program for New D Devices
Dexcom Announces Global Rollout of G7, as reported by Andrew Briskin for diaTribe.org, 10 October 2022. Dexcom, one of the leading manufacturers of CGM, announced on Oct. 4 that its latest product, the Dexcom G7, is now available for people with diabetes, ages 2...
Savvy Updates, 10/10/22: Indigo Continuous Multi-Metabolite (CMM) Sensor, T1D More Difficult/Dangerous for Girls
Indigo Diabetes enrolls first subject in multi-metabolite sensor trial was published by MedicalDevice-Network.com, 30 September 2022. Belgian diabetes device company Indigo Diabetes has enrolled the first participant in the Shine (multi-center, open-label,...
Savvy Updates, 10/3/22: EASD 2022 Highlights, Diabetes Product Waste, All About Fat, Bolusing for Fats & Proteins
Highlights From EASD 2022 was written by Andrew Briskin, Arvind Sommi and Natalie Sainz for diaTribe.org, 21 September 2022. Here’s a great overview of presentations at this year’s EASD (European Association for the Study of Diabetes) Annual Meeting, held...
Savvy Updates, 9/26/22: Medtronic Pumps & Cybersecurity Risk, Diabeloop Algorithm Increases TIR, T1D & UTIs, Moderate Diabetes Distress Even with CGM
FDA Warns of Cybersecurity Risk With Medtronic MiniMed 600 Series Insulin Pumps was reported by David Kerr, MD, for Healio.com/endocrinology, 20 September 2022. The FDA has issued an alert warning people with diabetes using a Medtronic MiniMed 630G or MiniMed 670G...
Savvy Updates, 9/19/22: Investor Lawsuit against Medtronic, Synthetic Human Gut Microbiome, Sex of Researcher Affects Study Outcomes, Loss of “Caring” in Healthcare
Investor lawsuit accuses Medtronic of failing to disclose insulin pump problems was posted by Mick Paul Taylor for MedTechDive.com, 13 September 2022. Investors have accused Medtronic of failing to disclose problems with its insulin pump business that...
More Diabetes Blogs